Decoy Therapeutics Inc (DCOY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Based on dividend-adjusted daily data since Jan 7, 2026, DCOY's average daily return is +0.19%, while the average monthly return is -0.56%.

Historically, 17% of months were positive and 83% were negative. The best month was May 2026 with a return of +47.4%, while the worst month was Mar 2026 at -20.1%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 4 months.

On a daily basis, DCOY closed higher 44% of trading days. The best single day was Jan 13, 2026 with a return of +53.4%, while the worst single day was Jan 14, 2026 at -30.4%.

Decoy Therapeutics Inc has an annualized alpha of 4.89%, beta of 1.74, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since January 08, 2026.

• This stock participated in 285.95% of S&P 500 Index downside but only 129.39% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for Decoy Therapeutics Inc (DCOY) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Decoy Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Decoy Therapeutics Inc was 70.60%, occurring on May 15, 2026. The portfolio has not yet recovered.

The current Decoy Therapeutics Inc drawdown is 42.60%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Decoy Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Decoy Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.